KRAS and pancreatic neoplasm: While some reports suggest that disrupting the PHB-CRAF interaction could impair oncogenic RAS-driven pancreatic cancer through the ERK-MAPK signaling pathway [67], it is widely believed that merely deleting CRAF produces minimal effects in KRAS-mutated pancreatic ductal adenocarcinomas (PDAC).